A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2019
At a glance
- Drugs SM-08502 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Samumed
- 03 Jan 2019 According to a Samumed media release, data from this study is expected in the first half of 2019.
- 11 Dec 2017 According to a Samumed media release, the first patient has been dosed in this trial.
- 04 Dec 2017 New trial record